AMG 330 Takes a BiTE out of Relapsed/Refractory AML

Farhad Ravandi-Kashani, MD, discusses results from the first-in-human trial showing the bispecific T-cell engager antibody was tolerable in patients with previously treated acute myeloid leukemia.

SHARE